An almost sure uptrend starts. Well high probability trade evident on the charts for DXCM.
Even high probability does not mean much sometimes due to changes in market conditions and external factors. so trade with Trailing Stop loss.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.57 EUR
490.60 M EUR
3.28 B EUR
385.37 M
About DexCom, Inc.
Sector
Industry
CEO
Kevin Ronald Sayer
Website
Headquarters
San Diego
Founded
1999
FIGI
BBG000NWV2W9
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of DC4 is 68.36 EUR — it has increased by 5.17% in the past 24 hours. Watch DexCom Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange DexCom Inc. stocks are traded under the ticker DC4.
DC4 stock has risen by 6.65% compared to the previous week, the month change is a 9.57% rise, over the last year DexCom Inc. has showed a −27.05% decrease.
We've gathered analysts' opinions on DexCom Inc. future price: according to them, DC4 price has a max estimate of 110.34 EUR and a min estimate of 68.96 EUR. Watch DC4 chart and read a more detailed DexCom Inc. stock forecast: see what analysts think of DexCom Inc. and suggest that you do with its stocks.
DC4 stock is 0.28% volatile and has beta coefficient of 0.89. Track DexCom Inc. stock price on the chart and check out the list of the most volatile stocks — is DexCom Inc. there?
Today DexCom Inc. has the market capitalization of 26.82 B, it has increased by 1.84% over the last week.
Yes, you can track DexCom Inc. financials in yearly and quarterly reports right on TradingView.
DexCom Inc. is going to release the next earnings report on Feb 6, 2025. Keep track of upcoming events with our Earnings Calendar.
DC4 earnings for the last quarter are 0.40 EUR per share, whereas the estimation was 0.39 EUR resulting in a 3.50% surprise. The estimated earnings for the next quarter are 0.49 EUR per share. See more details about DexCom Inc. earnings.
DexCom Inc. revenue for the last quarter amounts to 892.93 M EUR, despite the estimated figure of 889.56 M EUR. In the next quarter, revenue is expected to reach 1.04 B EUR.
DC4 net income for the last quarter is 120.89 M EUR, while the quarter before that showed 133.97 M EUR of net income which accounts for −9.76% change. Track more DexCom Inc. financial stats to get the full picture.
No, DC4 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 14, 2024, the company has 9.60 K employees. See our rating of the largest employees — is DexCom Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. DexCom Inc. EBITDA is 754.80 M EUR, and current EBITDA margin is 21.64%. See more stats in DexCom Inc. financial statements.
Like other stocks, DC4 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DexCom Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DexCom Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DexCom Inc. stock shows the neutral signal. See more of DexCom Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.